JUN 17, 2021 7:15 AM PDT

New COVID Drug Reduces Deaths in Patients with no Antibodies

WRITTEN BY: Annie Lennon

US drugmaker, Regeneron, in a partnership with Oxford University, has found that its new drug is capable of reducing COVID deaths by 20% when compared to standard treatments. 

The drug, known as REGEN-COV, is a combination of two monoclonal antibodies known as casirivimab and imdevimab. Both antibodies bind to different sites on the coronavirus’s spike protein and prevent it from infecting healthy cells. Using both antibodies together reduces the chance of the virus becoming resistant to the treatment. 

For the study, the researchers included 9,785 patients who were hospitalized with the SARS-CoV-2 virus. While half of the patients received REGEN-COV, the other half received standard treatment- either a steroid called dexamethasone or, for those with the most severe cases, an anti-inflammatory known as tocilizumab. 

Roughly two-thirds of the patients were seropositive (meaning they had already developed COVID-19 antibodies before treatment) while the remaining third were seronegative. 

In the end, the researchers found that seronegative patients who received REGEN-COV had hospital stays that were an average of four days shorter than those who received standard treatment. These patients were also less likely to need a ventilator. For patients who had developed antibodies, however, REGEN-COV had no effect. 

The researchers say that upon admission to hospital, patients should now be tested for antibodies to help doctors decide which treatment is best for them. Testing for antibodies, says trial investigator Martin Landray, should be just as typical a procedure as testing for blood sugar, blood pressure and oxygen levels. 

"These results are very exciting. The hope was that by giving a combination of antibodies targeting the SARS-CoV-2 virus we would be able to reduce the worst manifestations of COVID-19," said Sir Peter Horby, Joint Chief Investigator for the trial. 

"There was, however, great uncertainty about the value of antiviral therapies in late-stage COVID-19 disease. It is wonderful to learn that even in advanced COVID-19 disease, targeting the virus can reduce mortality in patients who have failed to mount an antibody response of their own."

 

Sources: RegeneronFierce PharmaThe Economist

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
MAR 12, 2022
Cannabis Sciences
The Role of Cannabinoid Receptors
MAR 12, 2022
The Role of Cannabinoid Receptors
A recent review of research on cannabinoid receptors and their influence on signaling pathways provides insights into ho ...
MAR 18, 2022
Cannabis Sciences
Amoebae's Role in Polyketide Production: Implications for Biotechnological Production of THC
MAR 18, 2022
Amoebae's Role in Polyketide Production: Implications for Biotechnological Production of THC
Researchers published a study confirming the discovery of a new process for producing active complex compounds in amoeba ...
MAR 24, 2022
Cardiology
A New Drug Effectively Treats Obesity
MAR 24, 2022
A New Drug Effectively Treats Obesity
Semaglutide has been called a "gamechanger" for treating obesity in adults.
MAR 29, 2022
Drug Discovery & Development
Nasal Spray Shows Promise Against All Variants of SARS-CoV-2
MAR 29, 2022
Nasal Spray Shows Promise Against All Variants of SARS-CoV-2
A compound delivered via a nasal spray can prevent and treat various COVID-19 variants in mice. The corresponding study ...
APR 12, 2022
Drug Discovery & Development
A wearable microphone that can listen to and monitor your body
APR 12, 2022
A wearable microphone that can listen to and monitor your body
The shirt you’re wearing right now helps keep you comfortable, protects you from the environment, and may be fashi ...
MAY 11, 2022
Cannabis Sciences
Legal Recreational Cannabis Reduces Prescription Drug Demand
MAY 11, 2022
Legal Recreational Cannabis Reduces Prescription Drug Demand
A research study published in Health Economics found a link between the availability of legal recreational cannabis, and ...
Loading Comments...